The main finding of this work is that TLR9 and TLR4 activation increases the expression of pro-survival genes, provides resistance to both reversible and irreversible proteasome inhibitors, and, at the same time, reduces the expression of BCMA, a broadly expressed surface protein and a target for bispecific antibody therapy and CAR T cells in MM. The gene discussed is TLR9; the disease is Miyoshi myopathy.